PENPenumbra, Inc.
Is the price fair?
Neither cheap nor expensive: cheap against its own history, but rich vs its sector.
Priced for ~20% a year FCF growth. Roughly in line with its three-year revenue growth of 17% a year.
Cheap vs its own history: P/E 78.5 vs a 121.7 median over 17 quarters (−36% vs median).
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What PEN's price assumes
Penumbra, Inc. trades at 78.5× earnings against 26.2× for the median Medical Devices name, more expensive than its own group.
Trailing P/E · Medical Devices median 26.2 · 2.99× the median: the market pays up for this one
- Price / sales
- 8.89
Price / sales · today's price, fiscal year to Dec 31, 2025
- Free cash flow yield
- 1.7%
Free cash flow yield · Medical Devices median 4.5%
- Growth the price implies
- +20%
Growth the price implies · The price pays for +20% free cash flow growth a year for a decade; the business has delivered +651% a year over the last three.
Details›
- Price / booktoday's price, fiscal year to Dec 31, 2025
- 8.74
- EV / EBITtoday's price, fiscal year to Dec 31, 2025
- 63.1
- EV / salestoday's price, fiscal year to Dec 31, 2025
- 8.51
- Healthcare median P/E509 names
- 26.2
- Medical Devices median P/E64 names
- 26.2
- Free cash flow, trailing twelve months
- $216M
- Market capitalisation
- $12.5B
- 3-year revenue growth
- +17%
- 3-year free cash flow growth
- +651%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $317.40 |
| Its own P/E history, median | $495.24 |
| Its own P/E history, upper quartile | $720.86 |
| 52-week range | $225.54 – $359.40 |
| Today | $319.42 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.